Abstract
We report a case of allergic bronchopulmonary aspergillosis (ABPA) that occurred in a man receiving infliximab for systemic sarcoidosis. His symptoms associated with ABPA were temporally related to his infliximab infusions. We suspect that infliximab disrupted the T-helper (Th) type 1-Th2 lymphocyte balance such that Th2 cytokines were left relatively unopposed, promoting the development of ABPA.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / adverse effects*
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects*
-
Aspergillosis, Allergic Bronchopulmonary / chemically induced*
-
Aspergillosis, Allergic Bronchopulmonary / immunology
-
Aspergillosis, Allergic Bronchopulmonary / physiopathology
-
Glucocorticoids / administration & dosage
-
Humans
-
Infliximab
-
Male
-
Middle Aged
-
Prednisone / administration & dosage
-
Respiratory Function Tests
-
Sarcoidosis / drug therapy*
-
T-Lymphocytes / immunology
Substances
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal
-
Glucocorticoids
-
Infliximab
-
Prednisone